Table 1 Baseline features of inpatients with decompensated cirrhosis integrally and strata by malnutrition and visceral obesity.

From: Global Leadership Initiative on Malnutrition-defined malnutrition coexisting with visceral adiposity predicted worse long-term all-cause mortality among inpatients with decompensated cirrhosis

 

ALL (n = 295)

WN (n = 61)

WO (n = 103)

MN (n = 76)

MO (n = 55)

P

Male (%)

143 (48.5)

19 (31.1)

48 (46.6)

36 (47.4)

40 (72.7)

<0.001

Age (years)

63 (56, 69)

57 (51, 63)

65 (58, 69)

63 (57, 71)

64 (58, 70)

<0.001

CTP score

8 (6.3, 9)

7 (6,9)

7 (6, 8)

8 (8, 10)

9 (7,10)

<0.001

MELD-Na score

7.6 (3.5, 13.2)

7.0 (3.5, 11.0)

5.1 (2.5, 9.5)

8.6 (5.0, 13.1)

12.6 (6.2, 19.8)

<0.001

NLR

3.1 (1.9, 4.7)

2.9 (1.4, 3.7)

2.7 (1.8, 4.3)

3.2 (2.0, 4.5)

4.0 (3.0, 6.9)

<0.001

PT-INR

1.3 (1.2, 1.5)

1.3 (1.1, 1.4)

1.3 (1.2, 1.3)

1.3 (1.1, 1.5)

1.4 (1.2, 1.5)

0.192

TBIL (μmol/L)

21.6 (14.1, 39.1)

19.5 (14.6, 31.7)

18.5 (12.6, 36.5)

25.4 (16.4, 40.4)

31 (14, 53)

0.047

ALT (U/L)

23 (15, 37)

24 (14, 34)

23 (16, 36)

25 (15, 41)

21 (14, 31)

0.508

AST (U/L)

31 (21, 51)

29 (20, 43)

29 (21, 47)

39 (25, 64)

33 (24, 53)

0.177

Albumin (g/L)

28 (25, 33)

30 (26, 34)

30 (26, 34)

27 (24, 31)

27 (23, 31)

0.001

Cr (μmol/L)

58 (48, 70)

51(45, 62)

59 (51, 70)

57 (49, 67)

65 (47, 82)

0.003

LDL-C (mmol/L)

2.1 (1.7, 2.6)

2.2 (1.8, 2.6)

2.0 (1.6, 2.6)

2.0 (1.6, 2.6)

2.3 (1.8, 2.7)

0.567

Sodium (mmol/L)

140 (137, 142)

141 (139, 143)

141 (139, 143)

139 (137, 142)

138 (136, 141)

<0.001

WBC (*109/L)

3.5 (2.4, 5.0)

3.1 (2.0, 4.0)

3.5 (2.5, 4.7)

3.8 (2.3, 4.9)

4.5 (3.4, 7.7)

<0.001

PLT (*109/L)

82 (59, 126)

76 (47, 119)

81 (64, 115)

87 (59, 134)

86 (63, 118)

0.308

Hemoglobin (g/L)

90 (72, 111)

87 (70, 111)

88 (72, 117)

86 (71, 103)

99 (82, 118)

0.084

SMI (cm2/m2)

43.9 (37.7, 49.7)

43.5 (35.8, 49.2)

48.1 (42.9, 53.9)

38.3 (34.0, 45.5)

43.2 (37.6, 48.6)

<0.001

BMI (kg/m2)

22.3 (19.1, 25.5)

21.4 (19.5, 24.1)

25.1 (23.1, 28.4)

18.3 (16.2, 20.1)

18.3 (16.2, 20.1)

<0.001

Hypertension (%)

86 (29.2)

8 (13.1)

39 (37.9)

12 (15.8)

27 (49.1)

<0.001

CHD (%)

22 (7.5)

1 (1.6)

7 (6.8)

8 (10.5)

6 (10.9)

0.128

T2DM (%)

66 (22.4)

12 (19.7)

30 (29.1)

12 (15.8)

12 (21.8)

0.182

Complications

Ascites (%)

     

<0.001

 NO

119 (40.3)

33 (54.1)

58 (56.3)

14 (18.4)

14 (25.5)

 

 Mild

82 (27.8)

14 (23.0)

31 (30.1)

20 (26.3)

17 (30.9)

 

 Moderate/Bulky

94 (31.9)

14 (23)

14 (13.6)

42 (55.3)

24 (43.6)

 

GEV (%)

207 (70.2)

46 (75.4)

73 (70.9)

53 (69.7)

35 (63.6)

0.586

HE (%)

21 (7.1)

1 (1.6)

10 (9.7)

3 (3.9)

7 (12.7)

0.051

Infection (%)

38 (12.9)

4 (6.6)

11 (10.7)

9 (11.8)

14 (25.5)

0.015

Etiology (%)

 Viral

71 (24.1)

23 (37.7)

25 (24.3)

16 (21.1)

7 (12.7)

0.014

 Alcoholic

71 (24.1)

6 (9.8)

22 (21.4)

15 (19.7)

28 (50.9)

<0.001

 Cholestasis/AILD

86 (29.2)

20 (32.8)

30 (29.1)

29 (38.1)

7 (12.7)

0.014

 Others

67 (22.7)

12 (19.7)

26 (25.2)

16 (21.1)

13 (23.7)

0.844

  1. WN well-nourished non-visceral obesity group, WO well-nourished visceral obesity group, MN malnourished non-visceral obesity group, MO malnourished visceral obesity group, CTP Child-Turcotte-Pugh, MELD-Na model for end-stage liver disease-sodium, NLR neutrophil-to-lymphocyte ratio, PT-INR prothrombin time-international normalized ratio, TBIL total bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, Cr creatinine, LDL-C low-density lipoprotein cholesterol, WBC white blood cell count, PLT platelet count, SMI skeletal muscle index, BMI body mass index, CHD coronary heart disease, T2DM type 2 diabetes, GEV gastroesophageal variceal hemorrhage, HE hepatic encephalopathy, AILD autoimmune liver disease.
Back to article page